AveXis (AVXS) Hit By Chardan Capital Downgrade; TELESITES SAB DE CV ORDINARY SHARES MEX (TSSLF) Shorts Decreased By 15.83%

AveXis (AVXS)‘s rating was cut by professional analysts at Chardan Capital from a Buy rating to a Neutral rating in an analyst report published on Friday, 13 April.

TELESITES SAB DE CV ORDINARY SHARES MEX (OTCMKTS:TSSLF) had a decrease of 15.83% in short interest. TSSLF’s SI was 12.65M shares in April as released by FINRA. Its down 15.83% from 15.03M shares previously. With 22,900 avg volume, 552 days are for TELESITES SAB DE CV ORDINARY SHARES MEX (OTCMKTS:TSSLF)’s short sellers to cover TSSLF’s short positions. The stock increased 2.78% or $0.02 during the last trading session, reaching $0.74. About shares traded. Telesites, S.A.B. de C.V. (OTCMKTS:TSSLF) has 0.00% since April 13, 2017 and is . It has underperformed by 11.55% the S&P500.

Telesites, S.A.B. de C.V. engages in leasing towers, roofs, and other telecommunications infrastructure in Mexico. The company has market cap of $2.29 billion. It also selects, acquires, installs, and operates telecommunication equipment. It currently has negative earnings.

AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. The company has market cap of $7.80 billion. The Company’s initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1. It currently has negative earnings. The firm also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases.

Analysts await AveXis, Inc. (NASDAQ:AVXS) to report earnings on May, 10. They expect $-1.95 earnings per share, down 82.24% or $0.88 from last year’s $-1.07 per share. After $-2.55 actual earnings per share reported by AveXis, Inc. for the previous quarter, Wall Street now forecasts -23.53% EPS growth.

The stock increased 0.25% or $0.54 during the last trading session, reaching $212.39. About 1.37 million shares traded or 70.63% up from the average. AveXis, Inc. (AVXS) has risen 59.28% since April 13, 2017 and is uptrending. It has outperformed by 47.73% the S&P500.

AveXis, Inc. (NASDAQ:AVXS) Ratings Chart

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: